Axa cut its position in shares of Agios Pharmaceuticals Inc (NASDAQ:AGIO) by 1.4% in the third quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 161,743 shares of the biopharmaceutical company’s stock after selling 2,244 shares during the quarter. Axa owned 0.33% of Agios Pharmaceuticals worth $10,796,000 at the end of the most recent quarter.
Other hedge funds have also recently bought and sold shares of the company. QS Investors LLC purchased a new stake in shares of Agios Pharmaceuticals in the second quarter worth approximately $144,000. Cubist Systematic Strategies LLC lifted its position in shares of Agios Pharmaceuticals by 1,041.0% in the second quarter. Cubist Systematic Strategies LLC now owns 3,423 shares of the biopharmaceutical company’s stock worth $176,000 after purchasing an additional 3,123 shares in the last quarter. Aperio Group LLC purchased a new stake in shares of Agios Pharmaceuticals in the second quarter worth approximately $206,000. Teacher Retirement System of Texas purchased a new stake in shares of Agios Pharmaceuticals in the third quarter worth approximately $225,000. Finally, S&CO Inc. purchased a new stake in shares of Agios Pharmaceuticals in the third quarter worth approximately $227,000. 93.79% of the stock is owned by institutional investors.
In other Agios Pharmaceuticals news, Director Lewis Clayton Jr. Cantley sold 4,000 shares of the stock in a transaction that occurred on Tuesday, October 17th. The stock was sold at an average price of $71.10, for a total transaction of $284,400.00. Following the transaction, the director now owns 84,394 shares in the company, valued at $6,000,413.40. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, insider Scott Biller sold 2,146 shares of the stock in a transaction that occurred on Monday, October 2nd. The shares were sold at an average price of $67.23, for a total value of $144,275.58. The disclosure for this sale can be found here. Insiders sold 127,746 shares of company stock worth $8,733,196 in the last 90 days. 5.43% of the stock is currently owned by corporate insiders.
Agios Pharmaceuticals (NASDAQ:AGIO) last released its quarterly earnings data on Wednesday, November 1st. The biopharmaceutical company reported ($1.59) EPS for the quarter, topping analysts’ consensus estimates of ($1.78) by $0.19. Agios Pharmaceuticals had a negative return on equity of 64.54% and a negative net margin of 679.14%. The firm had revenue of $11.35 million for the quarter, compared to the consensus estimate of $10.85 million. During the same quarter in the prior year, the company posted ($1.63) earnings per share. The firm’s revenue was up 26.4% on a year-over-year basis. sell-side analysts predict that Agios Pharmaceuticals Inc will post -6.59 EPS for the current fiscal year.
A number of analysts have recently issued reports on AGIO shares. Canaccord Genuity set a $90.00 price target on shares of Agios Pharmaceuticals and gave the stock a “buy” rating in a research report on Tuesday, December 12th. Oppenheimer reissued a “buy” rating and issued a $83.00 price target on shares of Agios Pharmaceuticals in a research report on Monday, December 11th. Cann reissued a “buy” rating on shares of Agios Pharmaceuticals in a research report on Tuesday, December 5th. SunTrust Banks set a $80.00 price target on shares of Agios Pharmaceuticals and gave the stock a “buy” rating in a research report on Sunday, November 19th. Finally, J P Morgan Chase & Co reissued a “buy” rating and issued a $76.00 price target on shares of Agios Pharmaceuticals in a research report on Monday, September 18th. One research analyst has rated the stock with a sell rating, two have given a hold rating and eleven have given a buy rating to the company’s stock. The company presently has an average rating of “Buy” and a consensus price target of $75.70.
TRADEMARK VIOLATION WARNING: “Axa Has $10.80 Million Holdings in Agios Pharmaceuticals Inc (AGIO)” was published by Sports Perspectives and is the sole property of of Sports Perspectives. If you are accessing this article on another website, it was stolen and republished in violation of US and international trademark & copyright legislation. The correct version of this article can be read at https://sportsperspectives.com/2017/12/21/axa-has-10-80-million-holdings-in-agios-pharmaceuticals-inc-agio.html.
Agios Pharmaceuticals Company Profile
Agios Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company’s therapeutic areas of focus are cancer and rare genetic metabolic disorders, which are a group of over 600 rare genetic diseases caused by mutations, or defects, of single metabolic genes. The Company’s cancer product candidates are enasidenib and ivosidenib (AG-120), which target mutated isocitrate dehydrogenase 2 (IDH2) and isocitrate dehydrogenase 1 (IDH1), respectively, and AG-881, which targets both mutated IDH1 and mutated IDH2.
Receive News & Ratings for Agios Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agios Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.